BriaCell Subsidiary to Acquire CD80 License

- The protein CD80 plays a key role in the immune system by acting as a "co-stimulatory" signal, essentially giving T-cells the final "go" order to attack threats like cancer cells. A soluble version of CD80 is being developed because it can perform a dual function: simultaneously blocking a signal that cancer cells use to hide (PD-L1) while also activating the T-cells. - Under the terms of the agreement, BriaCell will increase its ownership stake in its subsidiary BriaPro to approximately 78% and will provide up to $3 million in research funding. In exchange, BriaPro will pay a 2% royalty on future net sales of the product to the University of Maryland, Baltimore County (UMBC), the original patent holder. - This deal highlights two distinct career pathways in biotech. The initial discovery and design of a molecule like soluble CD80 often involves computational biology and bioinformatics, where specialists use computer models and data analysis to identify promising drug targets. - Subsequently, proving the therapy works in people falls to clinical research professionals. BriaCell's main drug candidate, Bria-IMT™, is currently in a large-scale Phase 3 clinical trial for metastatic breast cancer, a process managed by clinical research associates who work with patients and hospitals to gather data for FDA approval. - BriaPro, the subsidiary acquiring the license, is in a pre-clinical stage of development and is also working on novel antibodies targeting B7-H3, another protein found on cancer cells. The newly licensed soluble CD80 is a component of its broader "TILsRx" platform, designed to activate immune cells found within tumors. - Bioinformatics is essential in modern immunotherapy for more than just drug discovery. Data scientists use it to analyze tumor microenvironments and predict which patients are most likely to respond to a specific treatment, a key part of developing personalized medicine.